WCN24-342 ATACICEPT IN IGA NEPHROPATHY: CONTINUED PROTECTIVE TITERS TO DIPHTHERIA AND TETANUS AND BALANCED INFECTIONS VS PLACEBO WITH A FOCUS ON COVID-19

類似資料

• WCN24-342 ATACICEPT IN IGA NEPHROPATHY: CONTINUED PROTECTIVE TITERS TO DIPHTHERIA AND TETANUS AND BALANCED INFECTIONS VS PLACEBO WITH A FOCUS ON COVID-19
  著者:: Jonathan Barratt, 等
  出版事項: (2024-04-01)
• WCN24-1294 ATACICEPT REDUCES HEMATURIA AND SERUM GD-IGA1, BOTH ASSOCIATED WITH LONG-TERM RENAL OUTCOMES IN IGA NEPHROPATHY: 36-WEEK RESULTS FROM THE PHASE 2B ORIGIN STUDY
  著者:: Jonathan Barratt, 等
  出版事項: (2024-04-01)
• WCN25-2470 Long-term Results from the ORIGIN Phase 2b Study of Atacicept for the Treatment of IgAN
  著者:: Vivekanand Jha, 等
  出版事項: (2025-02-01)
• WCN25-2522 ORIGIN Extend: A Long-Term Extension Study of Atacicept in IgAN
  著者:: Jonathan Barratt, 等
  出版事項: (2025-02-01)
• Therapy of IgA nephropathy: time for a paradigm change
  著者:: Jonathan Barratt, 等
  出版事項: (2024-08-01)